Department of Emergency Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA
Fenway Institute, Boston, Massachusetts, USA.
BMJ Open. 2023 Jan 30;13(1):e067549. doi: 10.1136/bmjopen-2022-067549.
This quantitative survey sought to understand, among men who have sex with men (MSM) with potentially problematic substance use, the attitudes towards participation in research involving digital pill systems (DPS) for HIV pre-exposure prophylaxis (PrEP) adherence measurement, and the barriers and facilitators to research participation.
One-time, cross-sectional, online sampling-based survey.
US social networking app predominantly focused on MSM.
MSM without HIV who reported current use of oral PrEP, potentially problematic substance use and sexual activity in the past 3 months. A total of 157 participants were eligible, passed validity checks and enrolled.
Perceptions of DPS usefulness, accuracy and usability (System Usability Scale (SUS)); willingness and motivations to participate in DPS research; preferences for access to and feedback on DPS adherence data; data sharing considerations; and medical mistrust (Group-Based Medical Mistrust Scale (GBMMS)).
Most of the sample (N=157) was white (n=119, 75.8%), gay (n=124, 79.0%) and cisgender (n=150, 95.5%). The median age was 33 years (IQR: 14). The mean GBMMS score was 13.5 (SD=5.2), and the median SUS score was 70 (IQR: 27.5). In the past 3 months, 36.3% (n=57) reported frequent use of substances before or during sex, and 62.4% (n=98) engaged in condomless sex. While most were adherent to PrEP, approximately 34.4% (n=54) expressed significant worry about daily adherence. Participants wished to monitor their PrEP adherence daily (n=66, 42.0%) and 52% (n=82) were very willing to participate in DPS-based research. The majority were minimally concerned about sharing DPS-detected adherence data with research teams (n=126, 80.3%), and were extremely willing to share these data with healthcare providers (n=109, 69.4%).
In this sample, MSM without HIV who use substances reported willingness to use DPS to measure PrEP adherence in a research context, and identified benefits to accessing real-time, DPS-detected adherence data.
本定量调查旨在了解有潜在问题物质使用的男男性行为者(MSM)对参与涉及数字药丸系统(DPS)进行 HIV 暴露前预防(PrEP)依从性测量的研究的态度,以及参与研究的障碍和促进因素。
一次性、横断面、基于在线抽样的调查。
美国主要针对 MSM 的社交网络应用程序。
无 HIV 的 MSM,报告目前使用口服 PrEP、过去 3 个月内有潜在问题的物质使用和性行为。共有 157 名参与者符合条件、通过有效性检查并注册。
DPS 有用性、准确性和可用性的感知(系统可用性量表(SUS));参与 DPS 研究的意愿和动机;对获取和反馈 DPS 依从性数据的偏好;数据共享考虑因素;以及医疗不信任(基于群体的医疗不信任量表(GBMMS))。
大多数样本(N=157)为白人(n=119,75.8%)、男同性恋者(n=124,79.0%)和跨性别者(n=150,95.5%)。中位数年龄为 33 岁(IQR:14)。GBMMS 评分平均为 13.5(SD=5.2),SUS 评分中位数为 70(IQR:27.5)。在过去 3 个月中,36.3%(n=57)报告在性行为前或性行为中经常使用物质,62.4%(n=98)发生无保护性行为。尽管大多数人坚持服用 PrEP,但约 34.4%(n=54)对日常服用表示严重担忧。参与者希望每天监测他们的 PrEP 服用情况(n=66,42.0%),52%(n=82)非常愿意参与基于 DPS 的研究。大多数人对与研究团队共享 DPS 检测到的依从性数据的关注度最低(n=126,80.3%),并且非常愿意与医疗保健提供者共享这些数据(n=109,69.4%)。
在本样本中,无 HIV 的使用物质的 MSM 表示愿意在研究环境中使用 DPS 来测量 PrEP 依从性,并确定了获取实时、DPS 检测到的依从性数据的好处。